<DOC>
	<DOCNO>NCT01908452</DOCNO>
	<brief_summary>Objectives : The mechanism tardive dyskinesia ( TD ) remain unclear , although pathophysiologic theory propose mechanism dopamine receptor supersensitivity , degeneration cholinergic striatal interneurons , Î³-aminobutyric acid ( GABA ) depletion , excess free radical . Prior development second generation antipsychotic agent , tardive movement disorder widespread among neuroleptic treat patient . There great expectation new novel drug . Unfortunately , report tardive movement disturbance induce medication become frequent , although use less two decade . A recent study demonstrate schizophrenic schizoaffective patient suffer TD mean level pyridoxal 5'-phosphate ( PLP ) low limit normal range , patient without TD normal value . At time , open double-blind placebo-controlled , randomized clinical study show vitamin B6 effective treatment TD . Pyridoxal kinase key enzyme biosynthesis PLP , biologically active form vitamin B6 . Some publication report finding high vitamin B6 level consistent recent report low level PLP low activity pyridoxal kinase . It may explain functional need high-dose vitamin B6 supplementation subject TD . Methods : A multicenter study include 300 schizophrenia schizoaffective subject perform . The trial consist 2 part : first part single comparison pyridoxal kinase plasma activity patient without TD ; second part TD schizophrenia schizoaffective patient continue . It 12-week , randomize , double-blind placebo-controlled trial . Vitamin B6 ( 1200 mg/day ) placebo capsule add stable ongoing antipsychotic treatment 150 schizophrenia patient . Participants assess baseline every 2 week treatment till week 12 . Pyridoxal kinase activity compare patient positively respond vitamin B6 versus non responder . In addition , PLP level monitor baseline end study . A battery research tool use assessment movement disorder , psychopathology , side effect . The study perform along period 2 year .</brief_summary>
	<brief_title>Pyridoxal Kinase Activity Tardive Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Inpatients DSMIV diagnosis schizophrenia schizoaffective disorder without tardive dyskinesia ( TD ) Total ESRS score 20 subject TD Ability provide write informed consent Patients concurrent medical illness movement disorder resemble TD Patients receive vitamin medication Evidence substance alcohol abuse family history movement disorder . Pregnancy and/or lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>pyridoxal kinase activity</keyword>
	<keyword>plasma pyridoxal level</keyword>
</DOC>